Interferon control of the sterol metabolic network: Bidirectional molecular circuitry-mediating host protection

Frontiers in Immunology

Volumn 7, Issue DEC, 2016, Pages

  Robertson, Kevin A ^a   Ghazal, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

25 hydroxycholesterol; Cholesterol; Interferon; Metabolism; MiR 342 5p; MiRNA; Oxysterol; Sterol

Indexed keywords

25 HYDROXYCHOLESTEROL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CELLUBREVIN; CHOLESTEROL; GAMMA INTERFERON; HYPOCHOLESTEROLEMIC AGENT; INTERFERON; LISTERIOLYSIN O; MEVALONIC ACID; MICRORNA; OXYSTEROL; PIPERAZINE CITRATE; STEROID HORMONE; STEROL;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CELL MIGRATION; CHOLESTEROL ESTERIFICATION; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HYPOCHOLESTEROLEMIA; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INFLUENZA A; LEUKOCYTE; LIPID HOMEOSTASIS; LYMPHOBLASTOID CELL; MEMBRANE FUSION; METABOLIC CLEARANCE; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; STEROL METABOLISM; STEROL SYNTHESIS; T LYMPHOCYTE; TRANSCRIPTION INITIATION; VIRUS INFECTION; VIRUS MORPHOGENESIS;

EID: 85009360521     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00634     Document Type: Review

References (169)

1. Munger J, Bennett BD, Parikh A, Feng XJ, McArdle J, Rabitz HA, et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol (2008) 26(10):1179-86. doi:10.1038/nbt.1500
2. Spann N, Glass C. Sterols and oxysterols in immune cell function. Nat Immunol (2013) 14(9):893-900. doi:10.1038/ni.2681
3. Fessler MB. Regulation of adaptive immunity in health and disease by cholesterol metabolism. Curr Allergy Asthma Rep (2015) 15(8):48. doi:10.1007/s11882-015-0548-7
4. Blanc M, Hsieh WY, Robertson KA, Watterson S, Shui G, Lacaze P, et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol (2011) 9(3):e1000598. doi:10.1371/journal.pbio.1000598
5. Shibata N, Carlin A, Spann N, Saijo K, Morello C, McDonald J, et al. 25-Hydroxycholesterol activates the integrated stress response to reprogram transcription and translation in macrophages. J Biol Chem (2013) 288(50):35812-23. doi:10.1074/jbc.M113.519637
6. Lu H, Talbot S, Robertson K, Watterson S, Forster T, Roy D, et al. Rapid proteasomal elimination of 3-hydroxy-3-methylglutaryl-CoA reductase by interferon-gamma in primary macrophages requires endogenous 25-hydroxycholesterol synthesis. Steroids (2015) 99:219-29. doi:10.1016/j.steroids.2015.02.022
7. Robertson KA, Hsieh WY, Forster T, Blanc M, Lu H, Crick PJ, et al. An interferon regulated MicroRNA provides broad cell-intrinsic antiviral immunity through multihit host-directed targeting of the sterol pathway. PLoS Biol (2016) 14(3):e1002364. doi:10.1371/journal.pbio.1002364
8. Zilberstein A, Kimchi A, Schmidt A, Revel M. Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase. Proc Natl Acad Sci U S A (1978) 75(10):4734-8. doi:10.1073/pnas.75.10.4734
9. Muller M, Winnacker EL, Brem G. Molecular cloning of porcine Mx cDNAs: new members of a family of interferon-inducible proteins with homology to GTP-binding proteins. J Interferon Res (1992) 12(2):119-29. doi:10.1089/jir.1992.12.119
10. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science (1993) 261(5127):1445-8. doi:10.1126/science.7690156
11. Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-family proteins: the cell's first line of antiviral defense. Annu Rev Virol (2014) 1:261-83. doi:10.1146/annurev-virology-031413-085537
12. Baillie EE, Orr CW. Lowered high-density-lipoprotein cholesterol in viral illness. Clin Chem (1979) 25(5):817-8.
13. Cantell K, Ehnholm C, Mattila K, Kostiainen E. Interferon and high-density lipoproteins. N Engl J Med (1980) 302(18):1032-3. doi:10.1056/nejm198005013021817
14. Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES. Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis (1987) 67(2-3):261-7. doi:10.1016/0021-9150(87)90287-5
15. Borden EC, Rinehart JJ, Storer BE, Trump DL, Paulnock DM, Teitelbaum AP. Biological and clinical effects of interferon-beta ser at two doses. J Interferon Res (1990) 10(6):559-70. doi:10.1089/jir.1990.10.559
16. Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb Vasc Biol (1992) 12(9):1053-62. doi:10.1161/01.ATV.12.9.1053
17. Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis (1982) 2(1):68-73. doi:10.1161/01.ATV.2.1.68
18. Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, Tormey DC, et al. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. Metabolism (1984) 33(5):400-4. doi:10.1016/0026-0495(84)90136-7
19. Hawkins M, Horning S, Konrad M, Anderson S, Sielaff K, Rosno S, et al. Phase I evaluation of a synthetic mutant of beta-interferon. Cancer Res (1985) 45(11 Pt 2):5914-20.
20. Massaro ER, Borden EC, Hawkins MJ, Wiebe DA, Shrago E. Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. J Interferon Res (1986) 6(6):655-62. doi:10.1089/jir.1986.6.655
21. Olsen EA, Lichtenstein GR, Wilkinson WE. Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon). J Am Acad Dermatol (1988) 19(2 Pt 1):286-9. doi:10.1016/S0190-9622(88)70173-5
22. Boue F, Pastran Z, Spielmann M, Le Chevalier T, Subirana R, Sevin D, et al. A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients. Cancer Immunol Immunother (1990) 32(1):67-70. doi:10.1007/BF01741727
23. Soardo G, Pirisi M, Fonda M, Fabris C, Falleti E, Toniutto P, et al. Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res (1995) 15(8):705-12. doi:10.1089/jir.1995.15.705
24. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, Arai T, et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology (1997) 25(6):1502-6. doi:10.1002/hep.510250632
25. Fernández-Miranda C, Castellano G, Guijarro C, Fernández I, Schöebel N, Larumbe S, et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol (1998) 93(10):1901-4. doi:10.1111/j.1572-0241.1998.00546.x
26. Andrade RJ, García-Escaño MD, Valdivielso P, Alcántara R, Sánchez-Chaparro MA, González-Santos P. Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther (2000) 14(7):929-35. doi:10.1046/j.1365-2036.2000.00792.x
27. Morra VB, Coppola G, Orefice G, De Michele G, Vacca G, Filla A, et al. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology (2004) 62(5):829-30. doi:10.1212/01.WNL.0000113750.11090.67
28. Coppola G, Lanzillo R, Florio C, Orefice G, Vivo P, Ascione S, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol (2006) 13(9):1014-21. doi:10.1111/j.1468-1331.2006.01422.x
29. Mauss S, Berger F, Wehmeyer MH, Ingiliz P, Hueppe D, Lutz T, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther (2016). doi:10.3851/IMP3094
30. Kuo PT, Wilson AC, Goldstein RC, Schaub RG. Suppression of experimental atherosclerosis in rabbits by interferon-inducing agents. J Am Coll Cardiol (1984) 3(1):129-34. doi:10.1016/S0735-1097(84)80438-6
31. Pereira CA, Steffan AM, Koehren F, Douglas CR, Kirn A. Increased susceptibility of mice to MHV 3 infection induced by hypercholesterolemic diet: impairment of Kupffer cell function. Immunobiology (1987) 174(3):253-65. doi:10.1016/S0171-2985(87)80001-3
32. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell (2003) 12(4):805-16. doi:10.1016/S1097-2765(03)00384-8
33. York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell (2015) 163(7):1716-29. doi:10.1016/j.cell.2015.11.045
34. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 134(1):97-111. doi:10.1016/j.cell.2008.04.052
35. Armstrong AJ, Gebre AK, Parks JS, Hedrick CC. ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation. J Immunol (2010) 184(1):173-83. doi:10.4049/jimmunol.0902372
36. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation (2011) 124(2):185-95. doi:10.1161/CIRCULATIONAHA.110.006411
37. Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol (2013) 14(5):489-99. doi:10.1038/ni.2570
38. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 499(7459):485-90. doi:10.1038/nature12297
39. Janes PW, Ley SC, Magee AI. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J Cell Biol (1999) 147(2):447-61. doi:10.1083/jcb.147.2.447
40. Swamy M, Beck-Garcia K, Beck-Garcia E, Hartl FA, Morath A, Yousefi OS, et al. A cholesterol-based allostery model of T cell receptor phosphorylation. Immunity (2016) 44(5):1091-101. doi:10.1016/j.immuni.2016.04.011
41. Rougerie P, Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett (2012) 142(1-2):1-13. doi:10.1016/j.imlet.2011.12.003
42. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis (2004) 190(3):624-31. doi:10.1086/422329
43. Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, Quinton LJ, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med (2005) 202(6):761-9. doi:10.1084/jem.20050193
44. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 177(11):7980-9. doi:10.4049/jimmunol.177.11.7980
45. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 14(3):275-81. doi:10.1038/nm1710
46. Hu X, Wang Y, Hao LY, Liu X, Lesch CA, Sanchez BM, et al. Sterol metabolism controls T(H)17 differentiation by generating endogenous RORgamma agonists. Nat Chem Biol (2015) 11(2):141-7. doi:10.1038/nchembio.1714
47. Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, et al. Oxysterols are agonist ligands of RORgammat and drive Th17 cell differentiation. Proc Natl Acad Sci U S A (2014) 111(33):12163-8. doi:10.1073/pnas.1322807111
48. Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol (2002) 2(2):96-105. doi:10.1038/nri726
49. Karnell FG, Brezski RJ, King LB, Silverman MA, Monroe JG. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem (2005) 280(27):25621-8. doi:10.1074/jbc.M503162200
50. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol (2007) 18(5):616-26. doi:10.1016/j.semcdb.2007.07.009
51. Wilflingseder D, Stoiber H. Float on: lipid rafts in the lifecycle of HIV. Front Biosci (2007) 12:2124-35. doi:10.2741/2216
52. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity (2013) 38(1):106-18. doi:10.1016/j.immuni.2012.11.004
53. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 5(5):1292-324. doi:10.3390/v5051292
54. Seveau S. Multifaceted activity of listeriolysin O, the cholesterol-dependent cytolysin of Listeria monocytogenes. Subcell Biochem (2014) 80:161-95. doi:10.1007/978-94-017-8881-6_9
55. Bah SY, Dickinson P, Forster T, Kampmann B, Ghazal P. Immune oxysterols: role in mycobacterial infection and inflammation. J Steroid Biochem Mol Biol (2016). doi:10.1016/j.jsbmb.2016.04.015
56. Gong X, Qian H, Zhou X, Wu J, Wan T, Cao P, et al. Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer and Ebola infection. Cell (2016) 165(6):1467-78. doi:10.1016/j.cell.2016.05.022
57. Zawada KE, Wrona D, Rawle RJ, Kasson PM. Influenza viral membrane fusion is sensitive to sterol concentration but surprisingly robust to sterol chemical identity. Sci Rep (2016) 6:29842. doi:10.1038/srep29842
58. Manes S, del Real G, Martinez AC. Pathogens: raft hijackers. Nat Rev Immunol (2003) 3(7):557-68. doi:10.1038/nri1129
59. Gudleski-O'Regan N, Greco TM, Cristea IM, Shenk T. Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity. Cell Host Microbe (2012) 12(1):86-96. doi:10.1016/j.chom.2012.05.012
60. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother (2001) 45(4):1231-7. doi:10.1128/aac.45.4.1231-1237.2001
61. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 112(3):407-14. doi:10.1172/jci17704
62. Wang C, Gale M Jr, Keller BC, Huang H, Brown MS, Goldstein JL, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell (2005) 18(4):425-34. doi:10.1016/j.molcel.2005.04.004
63. Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, et al. Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptations. Chem Biol (2012) 19(2):218-27. doi:10.1016/j.chembiol.2011.12.016
64. Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe (2007) 2(4):229-39. doi:10.1016/j.chom.2007.09.003
65. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet (2007) 41:401-27. doi:10.1146/annurev.genet.41.110306.130315
66. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem (2000) 275(36):28240-5. doi:10.1074/jbc.M003337200
67. Joseph SB, Tontonoz P. LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol (2003) 3(2):192-7. doi:10.1016/S1471-4892(03)00009-2
68. Kandutsch AA, Chen HW. Regulation of sterol synthesis in cultured cells by oxygenated derivatives of cholesterol. J Cell Physiol (1975) 85(2 Pt 2 Suppl 1):415-24. doi:10.1002/jcp.1040850408
69. Miller SC, Melnykovych G. Regulation of cholesterol biosynthesis and esterification by 25-hydroxycholesterol in a macrophage-like cell line: uncoupling by progesterone. J Lipid Res (1984) 25(9):991-9.
70. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res (2009) 50(Suppl):S15-27. doi:10.1194/jlr.R800054-JLR200
71. Diczfalusy U. On the formation and possible biological role of 25-hydroxycholesterol. Biochimie (2013) 95(3):455-60. doi:10.1016/j.biochi.2012.06.016
72. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci U S A (2009) 106(39):16764-9. doi:10.1073/pnas.0909142106
73. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res (2009) 50(11):2258-64. doi:10.1194/jlr.M900107-JLR200
74. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol (2010) 88(6):1081-7. doi:10.1189/jlb.0610318
75. Kournikakis B, Murasko DM, Bozzola JJ. Ultrastructural study of biochemically modulated ADCC in HSV-1 infected and uninfected Chang liver cells. Microbios (1986) 48(195):81-91.
76. Moog C, Aubertin AM, Kirn A, Luu B. Oxysterols, but not cholesterol, inhibit human immunodeficiency virus replication in vitro. Antivir Chem Chemother (1998) 9(6):491-6. doi:10.1177/095632029800900605
77. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 99(24):15669-74. doi:10.1073/pnas.202608199
78. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A (2003) 100(26):15865-70. doi:10.1073/pnas.2237238100
79. Molina S, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2007) 46(3):411-9. doi:10.1016/j.jhep.2006.09.024
80. Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Belanger S, Supekova L, et al. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol (2009) 9:2. doi:10.1186/1472-6769-9-2
81. Howe D, Heinzen RA. Coxiella burnetii inhabits a cholesterol-rich vacuole and influences cellular cholesterol metabolism. Cell Microbiol (2006) 8(3):496-507. doi:10.1111/j.1462-5822.2005.00641.x
82. Cyster JG, Dang EV, Reboldi A, Yi T. 25-Hydroxycholesterols in innate and adaptive immunity. Nat Rev Immunol (2014) 14(11):731-43. doi:10.1038/nri3755
83. Gold ES, Ramsey SA, Sartain MJ, Selinummi J, Podolsky I, Rodriguez DJ, et al. ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol-induced lipid body formation. J Exp Med (2012) 209(4):807-17. doi:10.1084/jem.20111202
84. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2013) 38(1):92-105. doi:10.1016/j.immuni.2012.11.005
85. Roulin PS, Lotzerich M, Torta F, Tanner LB, van Kuppeveld FJ, Wenk MR, et al. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface. Cell Host Microbe (2014) 16(5):677-90. doi:10.1016/j.chom.2014.10.003
86. Faust JR, Luskey KL, Chin DJ, Goldstein JL, Brown MS. Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells. Proc Natl Acad Sci U S A (1982) 79(17):5205-9. doi:10.1073/pnas.79.17.5205
87. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol (2013) 87(8):4252-60. doi:10.1128/JVI.03546-12
88. Civra A, Cagno V, Donalisio M, Biasi F, Leonarduzzi G, Poli G, et al. Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol. Sci Rep (2014) 4:7487. doi:10.1038/srep07487
89. Iwamoto M, Watashi K, Tsukuda S, Aly HH, Fukasawa M, Fujimoto A, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem Biophys Res Commun (2014) 443(3):808-13. doi:10.1016/j.bbrc.2013.12.052
90. Anggakusuma, Romero-Brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, et al. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology (2015) 62(3):702-14. doi:10.1002/hep.27913
91. Dorobantu CM, Albulescu L, Harak C, Feng Q, van Kampen M, Strating JR, et al. Modulation of the host lipid landscape to promote RNA virus replication: the picornavirus encephalomyocarditis virus converges on the pathway used by hepatitis C virus. PLoS Pathog (2015) 11(9):e1005185. doi:10.1371/journal.ppat.1005185
92. Tani H, Shimojima M, Fukushi S, Yoshikawa T, Fukuma A, Taniguchi S, et al. Characterization of glycoprotein-mediated entry of severe fever with thrombocytopenia syndrome virus. J Virol (2016) 90(11):5292-301. doi:10.1128/JVI.00110-16
93. Mboko WP, Mounce BC, Emmer J, Darrah E, Patel SB, Tarakanova VL. Interferon regulatory factor 1 restricts gammaherpesvirus replication in primary immune cells. J Virol (2014) 88(12):6993-7004. doi:10.1128/JVI.00638-14
94. Xiang Y, Tang JJ, Tao W, Cao X, Song BL, Zhong J. Identification of cholesterol 25-hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against hepatitis C virus infection. J Virol (2015) 89(13):6805-16. doi:10.1128/JVI.00587-15
95. Chen Y, Wang S, Yi Z, Tian H, Aliyari R, Li Y, et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep (2014) 4:7242. doi:10.1038/srep07242
96. Ren R, Zhou X, He Y, Ke M, Wu J, Liu X, et al. Protein structure. Crystal structure of a mycobacterial Insig homolog provides insight into how these sensors monitor sterol levels. Science (2015) 349(6244):187-91. doi:10.1126/science.aab1091
97. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2010) 16(1):98-105. doi:10.1038/nm.2074
98. Wang F, Xia W, Liu F, Li J, Wang G, Gu J. Interferon regulator factor 1/retinoic inducible gene I (IRF1/RIG-I) axis mediates 25-hydroxycholesterol-induced interleukin-8 production in atherosclerosis. Cardiovasc Res (2012) 93(1):190-9. doi:10.1093/cvr/cvr260
99. Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca EJ, Paniccia A, et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J Exp Med (2013) 210(9):1711-28. doi:10.1084/jem.20130440
100. Reboldi A, Dang E, McDonald J, Liang G, Russell D, Cyster J. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science (2014) 345(6197):679-84. doi:10.1126/science.1254790
101. Gold ES, Diercks AH, Podolsky I, Podyminogin RL, Askovich PS, Treuting PM, et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci U S A (2014) 111(29):10666-71. doi:10.1073/pnas.1404271111
102. Jang J, Park S, Jin Hur H, Cho HJ, Hwang I, Pyo Kang Y, et al. 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome. Nat Commun (2016) 7:13129. doi:10.1038/ncomms13129
103. Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols direct immune cell migration via EBI2. Nature (2011) 475(7357):524-7. doi:10.1038/nature10280
104. Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols direct B-cell migration through EBI2. Nature (2011) 475(7357):519-23. doi:10.1038/nature10226
105. Yi T, Wang X, Kelly LM, An J, Xu Y, Sailer AW, et al. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity (2012) 37(3):535-48. doi:10.1016/j.immuni.2012.06.015
106. Kelly LM, Pereira JP, Yi T, Xu Y, Cyster JG. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and nonlymphoid tissues. J Immunol (2011) 187(6):3026-32. doi:10.4049/jimmunol.1101262
107. Gatto D, Paus D, Basten A, Mackay CR, Brink R. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity (2009) 31(2):259-69. doi:10.1016/j.immuni.2009.06.016
108. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature (2009) 460(7259):1122-6. doi:10.1038/nature08226
109. Yi T, Cyster JG. EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. Elife (2013) 2:e00757. doi:10.7554/eLife.00757
110. Li J, Lu E, Yi T, Cyster JG. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature (2016) 533(7601):110-4. doi:10.1038/nature17947
111. Singaravelu R, O'Hara S, Jones DM, Chen R, Taylor NG, Srinivasan P, et al. MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat Chem Biol (2015) 11(12):988-93. doi:10.1038/nchembio.1940
112. Olsen BN, Schlesinger PH, Ory DS, Baker NA. 25-Hydroxycholesterol increases the availability of cholesterol in phospholipid membranes. Biophys J (2011) 100(4):948-56. doi:10.1016/j.bpj.2010.12.3728
113. Utley TJ, Ducharme NA, Varthakavi V, Shepherd BE, Santangelo PJ, Lindquist ME, et al. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2. Proc Natl Acad Sci U S A (2008) 105(29):10209-14. doi:10.1073/pnas.0712144105
114. Bruce E, Digard P, Stuart A. The Rab11 pathway is required for influenza A virus budding and filament formation. J Virol (2010) 84(12):5848-59. doi:10.1128/JVI.00307-10
115. Bruce EA, Stuart A, McCaffrey MW, Digard P. Role of the Rab11 pathway in negative-strand virus assembly. Biochem Soc Trans (2012) 40(6):1409-15. doi:10.1042/BST20120166
116. Reinicke AT, Hutchinson JL, Magee AI, Mastroeni P, Trowsdale J, Kelly AP. A Salmonella typhimurium effector protein SifA is modified by host cell prenylation and S-acylation machinery. J Biol Chem (2005) 280(15):14620-7. doi:10.1074/jbc.M500076200
117. Price CT, Al-Quadan T, Santic M, Jones SC, Abu Kwaik Y. Exploitation of conserved eukaryotic host cell farnesylation machinery by an F-box effector of Legionella pneumophila. J Exp Med (2010) 207(8):1713-26. doi:10.1084/jem.20100771
118. Price CT, Jones SC, Amundson KE, Kwaik YA. Host-mediated post-translational prenylation of novel dot/icm-translocated effectors of Legionella pneumophila. Front Microbiol (2010) 1:131. doi:10.3389/fmicb.2010.00131
119. Ikegami T, Honda A, Miyazaki T, Kohjima M, Nakamuta M, Matsuzaki Y. Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem Biophys Res Commun (2014) 446(3):736-40. doi:10.1016/j.bbrc.2014.01.176
120. Jeon TI, Osborne TF. miRNA and cholesterol homeostasis. Biochim Biophys Acta (2016) 1861(12 Pt B):2041-6. doi:10.1016/j.bbalip.2016.01.005
121. Grady W, Parkin R, Mitchell P, Lee J, Kim Y, Tsuchiya K, et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene (2008) 27(27):3880-8. doi:10.1038/onc.2008.10
122. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene (2009) 28(45):4034-40. doi:10.1038/onc.2009.255
123. De Marchis ML, Ballarino M, Salvatori B, Puzzolo MC, Bozzoni I, Fatica A. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia (2009) 23(5):856-62. doi:10.1038/leu.2008.372
124. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-Campos J, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1-and microRNA-155-dependent pathway during atherosclerosis. Circulation (2013) 127(15):1609-19. doi:10.1161/circulationaha.112.000736
125. Wu C, Macleod I, Su AI. BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res (2013) 41(Database Issue):D561-5. doi:10.1093/nar/gks1114
126. Li X, Chen YT, Josson S, Mukhopadhyay NK, Kim J, Freeman MR, et al. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 8(8):e70987. doi:10.1371/journal.pone.0070987
127. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science (2005) 309(5740):1577-81. doi:10.1126/science.1113329
128. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 438(7068):685-9. doi:10.1038/nature04303
129. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 3(2):87-98. doi:10.1016/j.cmet.2006.01.005
130. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 122(8):2871-83. doi:10.1172/JCI63539
131. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 122(8):2884-97. doi:10.1172/JCI63455
132. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 449(7164):919-22. doi:10.1038/nature06205
133. Haussecker D, Kay MA. miR-122 continues to blaze the trail for microRNA therapeutics. Mol Ther (2010) 18(2):240-2. doi:10.1038/mt.2009.313
134. van der Ree MH, van der Meer AJ, van Nuenen AC, de Bruijne J, Ottosen S, Janssen HL, et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment Pharmacol Ther (2016) 43(1):102-13. doi:10.1111/apt.13432
135. Yang M, Liu W, Pellicane C, Sahyoun C, Joseph B, Gallo-Ebert C, et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J Lipid Res (2014) 55(2):226-38. doi:10.1194/jlr.M041335
136. Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si SY, et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol (2013) 33(10):1956-64. doi:10.1128/MCB.01580-12
137. Jiang H, Zhang J, Du Y, Jia X, Yang F, Si S, et al. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. Atherosclerosis (2015) 243(2):523-32. doi:10.1016/j.atherosclerosis.2015.10.026
138. Li M, Wang Q, Liu SA, Zhang JQ, Ju W, Quan M, et al. MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein. World J Gastroenterol (2015) 21(15):4517-25. doi:10.3748/wjg.v21.i15.4517
139. Buck AH, Perot J, Chisholm MA, Kumar DS, Tuddenham L, Cognat V, et al. Post-transcriptional regulation of miR-27 in murine cytomegalovirus infection. RNA (2010) 16(2):307-15. doi:10.1261/rna.1819210
140. Cazalla D, Yario T, Steitz J. Down-regulation of a host MicroRNA by a Herpesvirus saimiri noncoding RNA. Science (2010) 328(5985):1563-6. doi:10.1126/science.1187197
141. Marcinowski L, Tanguy M, Krmpotic A, Radle B, Lisnic VJ, Tuddenham L, et al. Degradation of cellular mir-27 by a novel, highly abundant viral transcript is important for efficient virus replication in vivo. PLoS Pathog (2012) 8(2):e1002510. doi:10.1371/journal.ppat.1002510
142. Guo YE, Riley KJ, Iwasaki A, Steitz JA. Alternative capture of noncoding RNAs or protein-coding genes by herpesviruses to alter host T cell function. Mol Cell (2014) 54(1):67-79. doi:10.1016/j.molcel.2014.03.025
143. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology (2013) 57(2):533-42. doi:10.1002/hep.25846
144. Shirasaki T, Honda M, Shimakami T, Horii R, Yamashita T, Sakai Y, et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol (2013) 87(9):5270-86. doi:10.1128/JVI.03022-12
145. Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology (2014) 59(1):98-108. doi:10.1002/hep.26634
146. Zheng Q, Hou J, Zhou Y, Yang Y, Cao X. Type I IFN-inducible downregulation of MicroRNA-27a feedback inhibits antiviral innate response by upregulating Siglec1/TRIM27. J Immunol (2016) 196(3):1317-26. doi:10.4049/jimmunol.1502134
147. Lai L, Azzam KM, Lin WC, Rai P, Lowe JM, Gabor KA, et al. MicroRNA-33 regulates the innate immune response via ATP binding cassette transporter-mediated remodeling of membrane microdomains. J Biol Chem (2016) 291(37):19651-60. doi:10.1074/jbc.M116.723056
148. Lv YC, Tang YY, Peng J, Zhao GJ, Yang J, Yao F, et al. MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1. Atherosclerosis (2014) 236(1):215-26. doi:10.1016/j.atherosclerosis.2014.07.005
149. Xue Y, Wei Z, Ding H, Wang Q, Zhou Z, Zheng S, et al. MicroRNA-19b/221/222 induces endothelial cell dysfunction via suppression of PGC-1alpha in the progression of atherosclerosis. Atherosclerosis (2015) 241(2):671-81. doi:10.1016/j.atherosclerosis.2015.06.031
150. Gunasekharan V, Laimins LA. Human papillomaviruses modulate microRNA 145 expression to directly control genome amplification. J Virol (2013) 87(10):6037-43. doi:10.1128/JVI.00153-13
151. Kang MH, Zhang LH, Wijesekara N, de Haan W, Butland S, Bhattacharjee A, et al. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol (2013) 33(12):2724-32. doi:10.1161/atvbaha.113.302004
152. Lin L, Hou J, Ma F, Wang P, Liu X, Li N, et al. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol (2013) 191(7):3896-904. doi:10.4049/jimmunol.1203450
153. Sala F, Aranda JF, Rotllan N, Ramirez CM, Aryal B, Elia L, et al. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost (2014) 112(4):796-802. doi:10.1160/TH13-11-0905
154. Gao F, Sun X, Wang L, Tang S, Yan C. Downregulation of MicroRNA-145 caused by hepatitis B virus X protein promotes expression of CUL5 and contributes to pathogenesis of hepatitis B virus-associated hepatocellular carcinoma. Cell Physiol Biochem (2015) 37(4):1547-59. doi:10.1159/000438522
155. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci U S A (2001) 98(26):15125-30. doi:10.1073/pnas.011593298
156. Wang X, Hinson ER, Cresswell P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe (2007) 2(2):96-105. doi:10.1016/j.chom.2007.06.009
157. Nasr N, Maddocks S, Turville SG, Harman AN, Woolger N, Helbig KJ, et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood (2012) 120(4):778-88. doi:10.1182/blood-2012-01-407395
158. Tan KS, Olfat F, Phoon MC, Hsu JP, Howe JL, Seet JE, et al. In vivo and in vitro studies on the antiviral activities of viperin against influenza H1N1 virus infection. J Gen Virol (2012) 93(Pt 6):1269-77. doi:10.1099/vir.0.040824-0
159. Helbig KJ, Beard MR. The role of viperin in the innate antiviral response. J Mol Biol (2014) 426(6):1210-9. doi:10.1016/j.jmb.2013.10.019
160. Fitzgerald KA. The interferon inducible gene: viperin. J Interferon Cytokine Res (2011) 31(1):131-5. doi:10.1089/jir.2010.0127
161. Tang HB, Lu ZL, Wei XK, Zhong TZ, Zhong YZ, Ouyang LX, et al. Viperin inhibits rabies virus replication via reduced cholesterol and sphingomyelin and is regulated upstream by TLR4. Sci Rep (2016) 6:30529. doi:10.1038/srep30529
162. Seo JY, Yaneva R, Hinson ER, Cresswell P. Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity. Science (2011) 332(6033):1093-7. doi:10.1126/science.1202007
163. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 139(7):1243-54. doi:10.1016/j.cell.2009.12.017
164. Smith S, Weston S, Kellam P, Marsh M. IFITM proteins-cellular inhibitors of viral entry. Curr Opin Virol (2014) 4:71-7. doi:10.1016/j.coviro.2013.11.004
165. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe (2013) 13(4):452-64. doi:10.1016/j.chom.2013.03.006
166. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog (2014) 10(4):e1004048. doi:10.1371/journal.ppat.1004048
167. Munoz-Moreno R, Cuesta-Geijo MA, Martinez-Romero C, Barrado-Gil L, Galindo I, Garcia-Sastre A, et al. Antiviral role of IFITM proteins in African swine fever virus infection. PLoS One (2016) 11(4):e0154366. doi:10.1371/journal.pone.0154366
168. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science (2010) 328(5985):1570-3. doi:10.1126/science.1189862
169. Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. J Antimicrob Chemother (2003) 52(6):883-6. doi:10.1093/jac/dkg490